Proprietary ExpreS2 Expression PlatformThe ExpreS2 insect-cell expression platform is a durable competitive asset: it enables production of complex antigens and VLP components that many rivals struggle to make, supports recurring service revenue from biotech clients, and underpins partnerable vaccine programs with long-term demand.

Low Leverage / Modest DebtVery low debt provides structural financial flexibility over months: the company can sustain R&D and partnership negotiations without immediate solvency pressure, has scope to raise incremental financing on better terms, and faces lower fixed-interest burdens while pursuing commercialization milestones.

Narrowing Net Losses Vs Prior YearA reduction in net losses indicates the business is moving toward improved operating efficiency or revenue mix. If sustained, this trend reduces cumulative cash burn, lessens fundraising frequency, and improves the probability of reaching break-even as platform services or partnered programs scale.

Bears Say

Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow is a structural weakness: the company consumes cash to fund operations and R&D rather than generating it, increasing reliance on external financing. Over 2–6 months this elevates dilution and execution risk if revenue or partner funding doesn't materialize.

Small, Volatile And Declining RevenueDeclining, volatile revenue undermines the sustainability of the service business that should monetize the platform. Without predictable revenue growth, the company struggles to self-fund development, weakening the commercial thesis for partnerships and prolonging dependence on external capital.

Eroding Equity And Asset BaseMaterial contraction of equity and assets over multiple years erodes the balance-sheet cushion, reducing borrowing capacity and increasing vulnerability to setbacks. This structural deterioration raises funding risk and could constrain strategic options such as scaling manufacturing or pursuing larger collaborations.

EXPRS2 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was kr4.35 and its highest was kr34.20 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is kr16.43M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

ExpreS2ion Biotech Holding AB’s upcoming earnings report date is May 19, 2026 which is in 58 days.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Feb 19, 2026. The company reported -kr2.406 earnings per share for the quarter, missing the consensus estimate of N/A by -kr2.406.

Is ExpreS2ion Biotech Holding AB overvalued?

According to Wall Street analysts ExpreS2ion Biotech Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 3,530,233 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -kr2.406 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.29%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in SE:EXPRS2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ExpreS2ion Biotech Holding AB

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.